San Ramon, CA – According to filings with the U.S. Securities and Exchange Commission, Bioventrix is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kenneth Miller played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bioventrix

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches. Less Invasive Ventricular Enhancement  or LIVE is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC TransCatheter Ventricular Enhancement System is a safer and less invasive alternative to surgical ventricular remodeling. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for  multidisciplinary heart teams and their patients by its proven clinical improvements.

To learn more about Bioventrix, visit http://www.bioventrix.com/

Contact:
Kenneth Miller, Chief Executive Officer
925-830-1000
kmiller@bioventrix.com
https://www.linkedin.com/in/ken-miller-3b75198/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved